Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.74 |
| ▸ | ATR | Q13535 | 5/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.57 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272431 | 0.85 | MTOR (1.00) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271772 | 0.84 | MTOR (0.74) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271911 | 0.83 | ATR (0.74) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271752 | 0.83 | MTOR (0.69) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1270798 | 0.82 | MTOR (0.86) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271818 | 0.82 | MTOR (0.70) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271439 | 0.81 | MTOR (0.81) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271937 | 0.81 | MTOR (0.66) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271776 | 0.80 | ATR (0.69) | MTORPIK3CAATRCYP2C9PIK3CD | |
| SCHEMBL1271420 | 0.80 | MTOR (1.00) | MTORPIK3CAATRCYP2C9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | TYMP, TYMS, PIK3CA | MTOR 4/4885PIK3CA 3/4885ATR 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.